About us
Dr. Ehab Amin
Founder of ValuePharma
"we execute what we preach and remain responsible to effect our advised plan"
Founded in 2008, after two decades of experience in Generic Pharmaceutical business in Middle East Region. ValuePharma is designed and structured to remain the ideal business partner for Pharmaceutical Manufacturers looking for launching their brands in the MENA region.
ValuePharma enjoys the services of highly qualified staff with enough years of regional experience in critical functions e.g. Regulatory and Brand Management In ValuePharma we believe in continuous training and selfeducation ,meeting the recent updates in business concepts and following up on the ever-changing business environment.
We believe in Value of People building a team behind your business development, challenging the difficulties for your Brand Value and our Business Success
Our Vision
MENA REGION AND THE EYE-SIGHTED PHARMERGING MARKETS
With Egypt Market seen and up-climping on the modified Pharma-emerging Markets’ List-Tier III, we still see Saudi, Iran, Algeria and next year’s Morocco meeting most of the qualifications of the Pharma-emerging markets world’s considerations.
Forecast by IMS to grow at 10% CAGR on 2011 forward till 2020, Middle East and Africa is still the second-best growing region on the map and continuously for the second decade.
In a business environment showing coalitions of forces and competitions on acquisitions …We still believe that the solid integrated coalesced corporations, as well as the solid stand-alone corporate organizations should aim faster on the geographical front.….looking at the fast-growing Middle East and Africa Region among the eye-sighted Pharma-emerging Markets.
Business Outframe
Own Brands / Licenses
We contract world know contract manufacturers to in-license patent products / unique formulas for our own operations in the Middle East. Our products are within classes of: food supplements / medical devices / cosmetics
Representative
We reserve our investments and partnership to pharmaceuticals’ known manufacturers owning there scientific & technical R&D for both Raw Materials.
Our target segments are into oncological products & biosimilars including anti-diabetics.
